MedTrace Logo

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

NCT06805617 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-07-29

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers.

The name of the study drug involved in this study is:

-Ivonescimab (a type of antibody)

Conditions

  • Salivary Gland Cancer
  • Advanced Salivary Gland Carcinoma
  • Metastatic Salivary Gland Cancer
  • Adenoid Cystic Carcinoma

Interventions

DRUG

Ivonescimab

An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

  • Summit Therapeutics

    collaborator INDUSTRY

  • Glenn J. Hanna

    lead OTHER

Principal Investigators

  • Glenn J Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2026-07-01
Completion
2027-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06805617 on ClinicalTrials.gov